ATOS vs. GBIO, ALIM, RIGL, LFCR, IXHL, OMER, TELO, ELYM, GTHX, and VERU
Should you be buying Atossa Therapeutics stock or one of its competitors? The main competitors of Atossa Therapeutics include Generation Bio (GBIO), Alimera Sciences (ALIM), Rigel Pharmaceuticals (RIGL), Lifecore Biomedical (LFCR), Incannex Healthcare (IXHL), Omeros (OMER), Telomir Pharmaceuticals (TELO), Eliem Therapeutics (ELYM), G1 Therapeutics (GTHX), and Veru (VERU). These companies are all part of the "pharmaceutical preparations" industry.
Atossa Therapeutics (NASDAQ:ATOS) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability.
Atossa Therapeutics has higher earnings, but lower revenue than Generation Bio. Atossa Therapeutics is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks.
Atossa Therapeutics' return on equity of -31.01% beat Generation Bio's return on equity.
Atossa Therapeutics currently has a consensus target price of $4.50, indicating a potential upside of 161.63%. Generation Bio has a consensus target price of $8.00, indicating a potential upside of 138.81%. Given Atossa Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Atossa Therapeutics is more favorable than Generation Bio.
12.7% of Atossa Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Generation Bio shares are owned by institutional investors. 7.8% of Atossa Therapeutics shares are owned by company insiders. Comparatively, 21.1% of Generation Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Atossa Therapeutics has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Generation Bio has a beta of 2.87, meaning that its share price is 187% more volatile than the S&P 500.
Atossa Therapeutics received 192 more outperform votes than Generation Bio when rated by MarketBeat users. However, 66.67% of users gave Generation Bio an outperform vote while only 64.96% of users gave Atossa Therapeutics an outperform vote.
In the previous week, Atossa Therapeutics' average media sentiment score of 0.00 equaled Generation Bio'saverage media sentiment score.
Summary
Atossa Therapeutics beats Generation Bio on 7 of the 13 factors compared between the two stocks.
Get Atossa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atossa Therapeutics Competitors List
Related Companies and Tools
